The PIM kinase family (PIM1, 2 and 3) have a central role in integrating growth and survival signals, and are expressed in a wide range of solid and hematological malignancies. We now confirm that PIM2 is overexpressed in multiple myeloma (MM) patients, and within MM group it is overexpressed in the high-risk MF subset (activation of proto-oncogenes MAF/MAFB). This is consistent with our finding of PIM2's role in key signaling pathways (IL-6, CD28 activation) that confer chemotherapy resistance in MM cells. These studies have identified a novel PIM2-selective non-ATP competitive inhibitor (JP11646) that has a 4 to 760-fold greater suppression of MM proliferation and viability than ATP-competitive PIM inhibitors. This increased efficacy is due not only to the inhibition of PIM2 kinase activity, but also to a novel mechanism involving specific downregulation of PIM2 mRNA and protein expression not seen with the ATP competitive inhibitors. Treatment with JP11646 in xenogeneic myeloma murine models demonstrated significant reduction in tumor burden and increased median survival. Altogether our findings suggest the existence of previously unrecognized feedback loop(s) where PIM2 kinase activity regulates PIM2 gene expression in malignant cells, and that JP11646 represents a novel class of PIM2 inhibitors that interdicts this feedback.
INTRODUCTION
The PIM (proviral insertion site in Moloney murine leukemia virus) family of serine/threonine kinases (PIM1, PIM2 and PIM3 1 ) have a central role in integrating growth signals that regulate a number of cellular pathways. [2] [3] [4] [5] [6] [7] PIMs are constitutively active, transcriptionally and translationally regulated 8, 9 and they are upregulated in a wide range of solid and hematological malignancies. 2, 10, 11 PIM2 specifically is upregulated in acute myeloid leukemia 12 and the plasma cell dyscrasia multiple myeloma (MM). 10, 11, [13] [14] [15] In myeloma, stromally-derived factors like IL-6 16 or the TNF family of cytokines, 13 via NFκB signaling 13 regulate PIM2 and its key role in MM cell survival and adaptation to stress (for example, to chemotherapy treatment). 13, 17, 18 This is in part mediated by PIM2 phosphorylation of its downstream targets TSC2 (and modulation of mTORC1 activity 19 ), the pro-apoptotic factor BAD and the protein translational inhibitor 4EBP1. PIM2 has also been implicated in the myeloma-mediated bone destruction via negative regulation of osteoblastogenesis 15, 20 and more recently in the regulation of the essential DNA damage response pathway in myeloma. 21 These observations suggest that therapeutically targeting PIM2 may have significant efficacy in MM. Of the PIM inhibitors 5 identified so far, most are small molecule ATP-competitive kinase inhibitors that affect multiple downstream pathways 22 and show more specificity to PIM1 and PIM3 than PIM2. [23] [24] [25] In preclinical studies the PIM2 selective inhibitor LGB321 22, 24 has been shown to induce MM cell death by inhibition of mTORC1 activity, 19 and in a phase I MM trial the pan-PIM inhibitor LGH447 19, 26 had acceptable toxicity with evidence for clinical efficacy. 15 But other PIM inhibitors (for example, SGI1776, 25 AZD1208, 15 AZD1897 15,27 ) have shown only limited preclinical single agent activity in myeloma. 23 Why the different PIM inhibitors have qualitatively different efficacy in MM is not clear, although compensatory feedback mechanisms have been implicated in some studies. 11, 28 We now report on a new non-ATP competitive PIM2-selective inhibitor JP11646 with potent anti-MM activity that in addition to inhibition of PIM kinase enzymatic activity has a novel mechanism of action downregulating PIM2 mRNA and protein expression. This latter effect overcomes the compensatory upregulation of PIM2 expression seen with the other PIM kinase inhibitors, and reveals previously unrecognized feedback loops regulating PIM2 expression and activity in MM.
MATERIALS AND METHODS

Cell culture
The aminopyrimidine kinase inhibitor JP11646 and other members of its family of inhibitors (Table 1) , LGB321 (Novartis, Berkeley, CA, USA) and AZD1208 (Astra Zeneca, London, UK) were synthesized and obtained from Jasco Pharmaceuticals (Woburn, MA, USA) and were used as 10 mM stocks in DMSO. The MM cell lines MM1.S (gift from Dr Stephen Rosen, Chicago, IL, USA), RPMI8226, U266 and KMS11 (ATCC, Manassas, VA, USA), were maintained in RPMI 1640 media (Mediatech Inc, Manassas, VA, USA) containing 10% FBS (Hyclone Inc., Logan, UT, USA), 1000 U/ml penicillin/ streptomycin, 4 mM L-glutamine, 0.1 mM non-essential amino acids, 1 mM sodium pyruvate. Recombinant IL-6 was purchased from R&D Systems (Minneapolis, MN, USA).
MA, USA). MM treatment with αCD28 mAb, neutralizing αIL6 and CTLA4Ig and flow cytometry for viability were carried out as described previously. 29 Gene expression analysis PIM2 expression analyses were carried out as described previously using data sets GSE6477 and GSE4204. 29 Proliferation and viability assays Viability assays for MM cells alone or with dendritic cells (DC) were performed in 96-well flat bottom plates (1x10 5 cells/well in 200 μl) treated as indicated, and viability estimated by flow cytometry after 24-48 h as described previously. 29 Proliferation assays (5 × 10 4 cells/ml for RPMI8226 and KMS11, 1.25 × 10 5 cells/ml for U266 and MM1.S) were carried out as described previously. 29 LC 50 and GI 50 values for viability and proliferation, respectively, were estimated using linear regression analysis.
Western immunoassays
Western blotting and immunoassays were performed as described previously. 29 Blots were treated with ECL Western Blotting Substrate (Thermo Fisher Scientific, Waltham, MA, USA) and visualized either by exposing to photographic film or acquired and analyzed using a LICOR Odyssey FC western blot documentation system (Lincoln, NE, USA). mRNA half-life analysis MM cells in culture were incubated with transcription inhibitor actinomycin D (5 μg/ml) and cells (3 × 10 6 ) were collected at different time points over 12 h, washed twice with cold PBS, RNA isolated (TRIZOL, Invitrogen Corp, Carlsbad, CA, USA) and quantified on a Synergy-H1 reader (BioTek Laboratories Inc, Winooski, VT, USA), and 10-15 μg of RNA was used for northern blotting and hybridization as described previously. 30 RT-PCR using forward primer 5′-TCGAAGTCGCACTGCTATGG-3′ and reverse 5′-TCGAGAGATCCACTCTGGGG-3′ on MM1.S total RNA was used to obtain a 389 bp amplicon that was labeled using α 32 P -dCTP (random primer DNA labeling system, Life Technologies, Grand Island, NY, USA) for use as PIM2 probe in northern blots.
NFκB luciferase reporter assays
Cells (2 × 10 6 cells) were transfected using the Amaxa nucleofector system (Lonza AG, Allendale, NJ, USA) with pGL4.32 (Promega, Madison, WI, USA) luciferase expression vector. After 24 h of transfection, cells were treated for a further 24-48 h as detailed. Samples were assayed for luciferase activity with Dual-Glo Luciferase Assay system (Promega) as per manufacturer's instructions.
Electromobility shift assays
Electromobility shift assays (EMSAs) to detect active NFκB dimers were carried out as described previously. 31 
Gene silencing
Cells were treated with PIM2 specific siRNA from Dharmacon, Inc., using Amaxa nucleofector as described by manufacturer (Lonza Biosystems, Walkersville, MD, USA), 24 h before initiation of experiments.
In vivo murine studies
All studies were carried out under RPCI IACUC-approved animal use protocols. SCID/SCID CBIgh.lblcrTac.Prkdcscid/Ros mice (Roswell Park Cancer Institute (RPCI) Laboratory Animal Resource) o5 weeks of age were irradiated at 300 rads using a Mark II Cesium irradiator 24 h before injecting them with MM1.S cells (5 × 10 6 ) subcutaneously under the skin on the left ventral flank. Once palpable subcutaneous tumors reached a volume of 100-200 mm 3 (length x width x width/2), the mice were randomly grouped 5-6/ group and drug treatments were initiated. For in vivo studies, JP11646 was prepared fresh (2.5 mg/ml, i.p.) in a proprietary carrier solution of 30% modified β-cyclodextrin (Ligand Pharmaceuticals Inc, La Jolla, CA, USA). Mice with necrotic tumors were euthanized as per IACUC guidelines. Median survival for each group was calculated using GraphPad Prism software and Pvalues were determined using the log rank (Mantel-Cox) test. Tumor volumes were assessed twice a week over the course of the experiments. In separate studies, mice with tumors were treated with JP11646 15 μg/gm and tumor harvested 0, 1, 3 and 6 h post injection. CD138 + MM cells were harvested from macerated tumors using αCD138 coated magnetic beads (Dynal beads, Invitrogen) as recommended by manufacturer, protein lysate prepared and analyzed by western immunoassays.
Statistical analysis
All experiments were performed at least twice and tests of significance was carried out using Student's t-test on Microsoft excel unless otherwise stated. Samples were always assayed in triplicate (n = 3) unless otherwise stated.
RESULTS
PIM2 is overexpressed in MM Our analysis of publicly available MM patient data sets shows increasing expression of PIM2 with disease progression from normal PC to myeloma (MM), with significantly greater expression in newly diagnosed MM patients (New) vs normal PC (Figure 1a , left). Re-analysis did not show any significant difference in PIM2 expression if the relapsed patients were removed from the total MM patient population (not shown). The increased PIM2 expression in MM vs normal controls was further verified by performing a similar analysis of PIM2 expression on another data set GSE39754 32 ( Supplementary Figure 1 ). This was specific to PIM2, as PIM1 expression significantly decreased from normal PC to MM (Figure 1a , center). PIM3 expression values being statistically insignificant were excluded. PIM1 expression in the whole MM group or newly diagnosed patients was significantly lower (~5 fold, P o0.0001) than PIM2 (Figure 1a , right), consistent with previous studies demonstrating the predominance of PIM2 overexpression in myeloma. 15 Within the myeloma patient subgroups, 33 PIM2 expression was significantly higher in the poor prognostic MF subgroup compared with the whole MM group (Figure 1b ). PIM2 expression in subgroup MS and PR also show significantly higher PIM2 expression from the whole MM population. Western immunoassays revealed similar levels of protein expression of all three isoforms of PIM2 (34, 38 and 40 kDa) in the MM cell lines RPMI8226, MM1.S, U266 and KMS11 ( Figure 1c ).
JP11646 is selective PIM2 inhibitor PIM2 overexpression in MM (in particular in the MF signature subgroup) suggests it may be a therapeutic target for small molecule kinase inhibition. In cell-free enzyme assays with PIM kinases, a novel series of PIM kinase inhibitors (JP11413-11662, US patents US 8 563 539 B2, US 8 901 145 B2, US 8 927 525 B2, US 9 073 903 B2, & US 9 157 077 B2) ( Table 1 ) demonstrated low nanomolar IC 50 values and showed greater inhibition of PIM2 than PIM1 or PIM3, with JP11646 being the most potent (IC 50 values of 24, 0.5 and 1 nM for PIM1, PIM2 and PIM3, respectively) ( Supplementary Table 1 ). JP11646 inhibitory effect on other kinases as assessed using a kinase selectivity panel was considerably less (Supplementary Table 1 ). The low K m of PIM2 for ATP 22 necessitates high potency of the ATP-competitive PIM2 inhibitors to block PIM2 enzymatic activity. Pharmacokinetic studies of JP11646 matched that of a freely reversible inhibitor standard ( Supplementary Figure 2A) , with slopes of 67 and 63, respectively, for test and standard. EC 50 concentrations show only a 1.67-fold increase across a 100-fold ATP change (0.15-0.25 nM, Supplementary Figure 2B ) and the replot of EC 50 values against ATP concentrations (Supplementary Figure 2C ) that match a non-competitive inhibitor are consistent with the non-competitive nature of JP11646 binding to PIM2 with respect to ATP. Using the Cheng and Prusoff algorithm, 34 a K i of 0.165 nM was determined for JP11646. Thus, JP11646 differs from other reported PIM2 inhibitors by being freely reversible and ATP non-competitive. Since inhibiting PIM kinases is known to affect myeloma survival, 13, 24, 25 and most of the current PIM inhibitors preferentially inhibit PIM1 or PIM3 over PIM2, we next examined the effect of selective PIM2 inhibition by JP11646 treatment on downstream PIM2 targets in myeloma cells.
Effect of JP11646-mediated inhibition on downstream molecular targets of PIM2
PIM2 mediates its pro-survival role by phosphorylating a number of downstream targets including 4EBP1, 35 BAD 22, 36, 37 and MCL1, 38 which all have central roles in MM cell proliferation and survival. PIM2 phosphorylation and inhibition of the negative regulator of translation 4E-BP1 is important for enhancing the unfolded protein response, 39 and phosphorylation of the pro-apoptotic factor BAD blocks BAD activation-induced cell death in myeloma. 3 MM1.S and U266 treated with JP11646 show a progressive decrease in p4EBP1 (S65) and pBAD (S112) over time, as well as decreases in the total levels of these proteins (which may be in part due to positive feedback from the phosphorylated forms on total expression; 7 Figure 2a ). In addition, there was a dosedependent decrease in the more potent phosphorylated form of the anti-apoptotic factor MCL1 (Ser159/Thr163) to 10% (MM1.S) or 30% (U266) of total MCL1 compared with untreated cells (Figure 2b , left). Total MCL1 levels also demonstrate a less marked dose-dependent decrease over time, likely due to the role of active pMCL1 in sustaining total MCL1 levels. 38 Silencing PIM2 with siRNA ( Figure 2b , right) produce similar decreases in pBAD and p4EBP1 levels, suggesting that the effect of JP11646 is due to its inhibition of PIM2. Pathway analysis of whole transcriptome analysis of untreated vs JP11646 treated MM1.S and U266 cells ( Supplementary Table 2 ) demonstrated in both cell lines a disproportionate effect on components of nucleotide and amino acid metabolism pathways as well as the unfolded protein response response pathway (Supplementary Table 3 ).
Effect of JP11646-mediated PIM2 inhibition on MM proliferation and viability
We next examined the effect of PIM2 inhibition by JP11646 on MM proliferation and survival. We found that the anti-proliferative effect of JP11646 treatment was greatest in the MF-signature cell line MM1.S (growth inhibition (GI 50 ) of 5 nM), although the sensitivity against the other MF-signature cell line RPMI8226 (GI 50 of 36 nM) was similar to the non-MF cell lines (15 nM for MS signature KMS11, and 37 nM for CD1 signature U266; Table 2 , Supplementary Figure 3A) . However, JP11646's inhibition of cell viability was more pronounced for the MF-signature cell lines RPMI8226 and MM1.S (LC 50 values of 46 and 16 nM, respectively), in comparison with 67 and 222 nM for KMS11 and U266, respectively ( Table 2 , Supplementary Figure 3B ). When compared with the ATP-competitive PIM inhibitors, JP11646 show 480-fold and 44-fold greater inhibition of proliferation (GI 50 of 5-37 nM) vs AZD1208 (0.7-4.7 μM) or LGB321 (22-343 nM) respectively ( Table 2 , Supplementary  Figure 3C -F). For viability, JP11646 showed 4760-fold and 4230fold inhibition (LC 50 of 16-222 nM) compared with AZD1208 (23-56 μM) and LGB321 (0.5-25 μM), respectively ( Table 2 , Supplementary Figure 3G -J). Like JP116464, both AZD1208 and LGB321 were more effective inducing cell death in the MFsignature cell lines.
In addition to single agent activity, the ability to sensitize MM cells in combination with other anti-myeloma chemotherapies was tested using sublethal concentrations of JP11646 (10 nM for MM1.S (viability of 87%) and 100 nM for U266 (viability of 81%)). In MM1.S, cell viability with melphalan decreased from 36% (alone) to 15% in combination with JP11646; with dexamethasone, from 55% (alone) to 8% in combination with JP11646; and with bortezomib from 18% (alone) to 2% in combination with JP11646 ( Supplementary Figure 3K, left) . In the more resistant cell line U266, viability in melphalan alone (58%) or bortezomib alone (85%) was significantly reduced to 39 or 53% respectively in combination with JP11646 ( Supplementary  Figure 3K , right). Consistent with the single agent findings, there was greater efficacy of the bortezomib+JP11646 combination in MF-signature cell line MM1.S than with CD1-signature cell line U266.
These data demonstrate that PIM inhibition with JP11646 causes greater inhibition of proliferation and cell viability than seen with the other ATP-competitive inhibitors, despite the equivalent ability to inhibit PIM kinase activity in cell-free assays. 15, 40 One on-target explanation for this disparity is that inhibition with JP11646 is affecting PIM2 kinase activity through mechanisms in addition to blocking enzymatic activity.
JP11646 treatment inhibits PIM2 expression in myeloma cells Since the PIMs are constitutively active, total activity is regulated by PIM expression levels. We found that in contrast to the unchanged-to-upregulated expression of PIM2 following treatment with LC 50 doses of AZD1208 or LGB321, JP11646 treatment decreased PIM2 protein and mRNA levels to undetectable levels (Figure 3a, top) . These findings suggest that inhibition of PIM2 kinase activity can induce compensatory upregulation of PIM2 expression, and the ability of JP11646 to also inhibit PIM2 expression may account for its increased potency. The concentration and time dependency of JP11646 effect on PIM2 expression was further characterized by treating MM cells with increasing doses over 24 h, or treating with LC 50 doses over a time course. In both MM1.S and U266, decreases in PIM2 expression were observed at concentrations as low as 12.5 and 50 nM, with 90% loss at 100 and 400 nM respectively (Figure 3a, bottom) . Over time, a slight increase at 1 h was followed by a progressive decrease between 3 and 6 h (86 and 83%, respectively). This was specific to PIM2, as in the same experiment there was a concomitant increase in PIM1 and PIM3 expression ( Figure 3b ). Similar decreases in PIM2 mRNA levels were also observed (30% and 16% of control, respectively; Figure 3c, left) . Surprisingly, in normal primary human peripheral blood mononuclear cells (PBMC) there was no effect of JP11646 on PIM2 expression, even though the substantial decreases in p4EBP1 indicated inhibition of PIM2 kinase activity (Figure 3c, right) . Why the effect on PIM2 expression in normal PBMC vs MM cells is different is not clear, although one possibility is that normal PBMC are largely quiescent.
Since JP11646 is a reversible inhibitor, we examined whether sustained treatment was necessary for the inhibition of PIM2 expression. MM1.S and U266 treated with JP11646 for 24 h, then washed and cultured in media without JP11646, showed continued inhibition of both PIM2 protein (Figure 3d , Upper) and mRNA expression (Figure 3d , Lower) over 12 (MM1.S) to 24 h (U266)-and also continued to die at similar rates as cells continuously cultured in the presence of JP11646 ( Supplementary Figure 4) .
Loss of PIM2 mRNA expression suggests that either gene transcription or mRNA stability was being affected, as PIM mRNA are known to have destabilizing AUUUA sequences in their 3' regions. 41 The half-life (t 1/2 ) of PIM2 mRNA in untreated MM1.S and U266 cells following actinomycin D treatment (3.2 h and 5.6 h, respectively (Supplementary Figure 5) ), was similar to what we observed with JP11646 treatment (Figures 3d, 6 and 5.9 h, respectively), suggesting that PIM2 mRNA stability was not being affected, and instead points to an effect at the level of PIM2 transcription.
PIM2 inhibition overcomes growth factor and pro-survival signaling in myeloma
The preceding data suggests that JP11646 represents a new class of PIM2 inhibitors with a novel mechanism of action that simultaneously inhibits PIM2 kinase activity and gene expression -and this affords greater potency in part by abrogating compensatory upregulation of PIM2 expression. The pathways that regulate PIM2 expression are not well characterized, 5 but current studies 13, [42] [43] [44] [45] suggest interlocking loops where growth factor signals regulate PIM2 expression and that PIM2 is part To assess this in the context of MM, we first examined the effect of the important stromally-derived MM survival factor IL-6 46,47 on PIM2 expression, and the effect of PIM2 inhibition on IL-6 mediated cellular responses. In MM1.S and U266, recombinant IL-6 (rIL-6) induced upregulation of PIM2 (3.2 and 1.3 fold, respectively), which was reversed by neutralizing αIL6 antibody (Figure 4a, Left) . JP11646-mediated inhibition of PIM2 expression (480% in MM1.S and 490% in U266) was partially reversed by rIL-6 in MM1.S, along with partial restoration of phospho-and total 4EBP1 levels. But IL-6 had no effect in U266, possibly because an autocrine IL-6 growth loop makes U266 less responsive to exogenous IL-6. 48 Interestingly, IL-6 had no effect on PIM2 mRNA expression in either setting (Figure 4a, right) , suggesting IL-6 may be regulating PIM2 expression post-transcriptionally.
In addition to IL-6 regulation of PIM2 expression, we also found that PIM2 inhibition by sublethal doses of JP11646 completely blocked rIL-6-induced MM cell proliferation (Figure 4b ). Altogether these findings indicate that PIM2 is both a target of IL-6 signaling as well as a component of the biological response pathways to IL-6 signaling.
We had previously shown that the T cell costimulatory molecule CD28, also overexpressed in poor prognostic MF-signature MM patient subgroup, 29 when activated directly (agonistic antibodies) or indirectly via coculture with CD80 + /CD86 + DC confers resistance to chemotherapy-induced cell death. 29, 31, 49, 50 We first assessed whether PIM2 was a component of the CD28-mediated pro-survival effect in MM-DC cocultures. We found that DCmediated protection of MM1.S cells against death caused by melphalan, dexamethasone or serum starvation was completely reversed by PIM2 inhibition by sublethal concentrations of JP11646 (Figure 4c , Left)-with no effect on DC expression of CD28 ligands CD80/CD86 (Figure 4c , Right) or DC viability (not shown). Similarly, the pro-survival effect of directly activating CD28 on MM cells alone with agonistic mAb was also completely reversed by JP11646 treatment (Figure 4d, Left) . Furthermore, CD28 activation had no effect on JP11646-induced reduction of PIM2 expression or its phosphorylation of its targets (Supplementary Figure 6) . Conversely, blocking CD28 activation with the inhibitor CTLA4-Ig (MM cells express both CD28 and CD86, which transduces a cis pro-survival signal between MM cells themselves 29, 51 ) significantly enhanced JP11646 cytotoxicity in MM1.S (Figure 4d , Right). These findings suggest there is previously unrecognized crosstalk between the CD28 and PIM2 signaling pathways, and this is further supported by the observation that CTLA4-Ig treatment also decreased PIM2 expression (Figure 4d right, inset), suggesting that constitutive CD28 signaling may also be involved in regulation of PIM2 expression.
Inhibition of PIM2 inhibits CD28-induced NFκB signaling in myeloma
A major survival signal induced downstream of CD28 activation in MM is NFκB 31 , but a role for PIM2 in the CD28 → NFκB pathway has not been previously identified. We found that although PIM2 inhibition with JP11646 alone had little effect on basal NFκB signaling, it blocked NFκB activation-induced by anti-CD28 mAb (Figure 5a, Left) . This was also seen when PIM2 inhibition was accomplished with siRNA knockdown instead of JP11646 (Figure 5a, Right) , suggesting that PIM2 is in the CD28 → NFκB signaling pathway. In addition, consistent with sensitization of MM cells to JP11646 by CTLA4-Ig, we found that CTLA4-Ig+sublethal doses of JP11646 inhibited NFκB signaling to substantially lower levels than with either alone (Figure 5b ). Similar effects were also observed with AZD1208 and LGB321 (Figure 5c ). The loss of NFκB signaling was supported by NFκB luciferase reporter assays, where there was a dose-dependent decrease in luciferase activity-with RPMI8226 showing a plateau in response (Figure 5d , Left). When NFκB activity was assessed at a fixed concentration of JP11646 over time, we observed a brief transient increase at 1 h followed by a progressive decrease in activity over 12 h (Figure 5d, Right) . These findings suggest the previously unrecognized possibility that PIM2 is involved in NFκB signaling downstream of CD28 and other pathways.
In vivo efficacy of PIM2 inhibition To assess whether PIM2 inhibition by JP11646 had in vivo anti-MM efficacy, scid/scid mice were implanted with MM1.S, and after tumor reached 100 mm 3 , these mice were treated with JP11646 at 10 (JP10) or 15 μg/gm (JP15) via i.p. injection given consecutively for 2 or 3 times a week. The JP15 dosage was found to have superior anti-tumor efficacy when compared with vehicle alone or JP10 (Figure 6a ) with toxicity limited to weight loss that was readily managed with dietary supplementation. At week 2, the relative tumor volumes were reduced to 49% (JP10 group) or 89% (JP15) of the untreated controls. At the end of week 4, JP15 group showed 491% decrease in tumor compared with control at week 2 (control was euthanized at week 2 due to necrotic tumors). Mice in the JP10 group continued to see a growth in tumor volume, though not at the same rate as in the vehicle control group (Figure 6b , Left). Median survival in vehicle control group was 17 days, 27 days for JP10 and 48 days for JP15 group (Figure 6b , right) as calculated by Kaplan-Meier analysis (Figure 6c ). After treatment was stopped at day 27, two of the three surviving mice in the JP15 group did not show any regrowth of tumors over the remaining 2 weeks of observation.
To examine whether decrease in substrate phosphorylation by JP11646 in vitro happened in vivo, SCID/SCID mice were implanted subcutaneously with MM1.S and when tumors reached 100 mm 3 were given a single dose of JP11646 at 15 μg/gm, and tumors harvested at different time points post injection. Western assays show a similar time dependent decrease in PIM2 levels with subsequent drop in both pBAD, p4E-BP1 and total MCL1 as we have observed in vitro (Figure 6c ).
DISCUSSION
The pleotropic roles of the PIM kinases in proliferation and survival in cancer, the overexpression of PIM2 in MM (especially in the poor prognosis MF-signature group) and reduced potential toxicity as compared with pan-PIM inhibition underscores the rationale to target PIM2. 52 Although some PIM2 inhibitors (LGB321 19, 22, 24 and LGH447 19, 26 ) show promising anti-MM efficacy, 15 others do not 23 -and the basis for these differences remains largely unclear.
We now report on a novel non-ATP competitive PIM2 selective inhibitor JP11646 that not only inhibits kinase activity and downstream phosphorylation of PIM2 targets 4EBP1, BAD and MCL1, but also has the unique ability to simultaneously inhibit expression of PIM2 at the protein and mRNA levels, both in vitro and in vivo. This likely accounts for its great potency inhibiting MM cell proliferation and viability compared with the ATP-competitive PIM inhibitors (AZD1208, LGB321) which do not inhibit PIM2 expression-and in fact, induce a compensatory increase in PIM2 expression that likely blunts their anti-proliferative/pro-apoptotic effect. The effect of JP11646 inhibition on both PIM2 kinase activity and expression suggest the existence of additional previously unrecognized feedback loops, as what controls PIM expression in general is not well characterized. To begin to understand this better, we looked at potential off-target effects of JP11646 by screening it against a panel of 150 kinases using Millipore's KinaseProfiler (Billerica, MA, USA). Although PIM2 gave the lowest IC 50 of 0.5 nM, the only other kinase that showed comparable inhibition was the PIM family member PIM3 to an IC 50 3 tumors were treated with a single dose of JP11646 at 15 mg/kg, and then tumors collected immediately or after 1,3 or 6 h, lysed and immunoassayed for PIM2, pBAD (S112), BAD, MCL1, pEBP1 (S65), total 4EBP1 or Tubulin. *P o0.05, **P o0.01, ***P o0.001, NS, not signficant.
Targeting PIM2 in multiple myeloma of 41 nM (42 fold of PIM2), whereas seven more kinases gave IC 50 values 36-197-fold greater than PIM2 (Supplementary Table 1 ). The rest of the kinases gave IC 50 values 4200 fold that of PIM2 (not shown). Gene expression analysis of MM cells treated with JP11646 over 24 h show several common genes that are most upregulated or downregulated (Supplementary Table 2 ). Pathway analysis also show dysregulation of genes that are part of essential nucleotide/amino acid metabolism and the unfolded protein response response pathways ( Supplementary Table 3 ). However, given that PIM2 appears to be involved in multiple signaling pathways in myeloma (for example, IL-6 and CD28 in our studies), it is difficult to definitively define from the analysis an 'off target' effect of JP11646. We also found that unlike PIM2, JP11646 treatment induced either no change (U266) or a 1.8-fold increase (MM1.S) in PIM1 gene expression. Although it is certainly possible that JP11646 is affecting some pathway other than PIM2 that regulates PIM expression, the observations that the effect of JP11646 inhibition is mirrored by PIM2 knockdown (suggesting PIM2 specificity) while not affecting other PIM members (PIM1/3) at least in U266 point to a particular role for PIM2 signaling in regulating its own expression.
But it remains to be investigated whether JP11646 represents a new class of dual-action PIM2 inhibitors that alters PIM2 signaling in a qualitatively different manner than other ATP-competitive PIM inhibitors to inhibit PIM2 expression, or by interdicting other components of the feedback loops.
We have also found that JP11646 downregulates PIM2 expression in acute myeloid leukemia and a wide range of solid tumor cell lines (KB and GF, manuscript in preparation), indicating that this effect is not myeloma-specific. Why JP11646 inhibits PIM2 kinase activity but not PIM2 expression in normal human PBMC is not clear, but raises the possibility that this effect in malignant cells is due to proliferation and/or aberrant growth signals-and that JP11646 is inhibiting some component (PIM2?) in the downstream signaling cascades (STAT3, STAT5, NFκB) that also drive PIM2 transcription. 7, 9, 53, 54 However, this does not explain why IL-6 (which induces STAT3 and STAT5 signaling) has no effect on constitutive PIM2 mRNA expression, and cannot rescue JP11646-induced downregulation in MM cells. Nor does it explain why AZD1208 or LGB321, which we have shown can inhibit NFκB signaling to a similar extent as JP11646, do not affect PIM2 expression. Alternatively, JP11646 may be directly affecting the transcriptional regulation of PIM2, as many transcription factors and associated machinery are regulated by phosphorylation. For example, the FoxP3 transcription factor regulates PIM2 gene expression in Tregs. 55 Further studies are underway to define the underlying mechanisms.
The ability of JP11646 to abrogate key pro-myeloma effects of stromal IL-6 and DC-mediated CD28 activation is of particular clinical significance, given the central role the microenvironment has in the survival and therapy-resistance of MM cells. The additional complexity that PIM2 may be both a component of the upstream signal transduction pathway (of both IL-6 and CD28) and a downstream gene target of these signaling pathways further suggests interlocking feedback loops where PIM2 function affects PIM2 expression. Our findings that PIM2 is involved in activating the key NFκB pro-survival pathway (also reported in pro-B cells 56 and hepatocellular carcinoma 57 ) suggests the molecular mechanism by which the PIM2 inhibitors kill MM cells. These multiple anti-MM effects of JP11646 inhibition are reflected by in vivo efficacy, with complete eradication of tumors in 40% of treated mice. Additionally, recent studies using small molecule inhibitors of PIM2 or siRNA show that PIM2 inhibition can reverse bone loss and tumor progression in MM, 20 suggesting that in addition to a direct anti-myeloma effect that JP11646 may ameliorate MM-associated bony disease.
Altogether our results suggest the existence of previously unrecognized feedback loop(s) where PIM2 kinase activity regulates PIM2 gene expression in MM and other malignant cells, and that JP11646 represents a novel class of PIM2 inhibitors that interdicts this feedback. This abrogates the upregulation of PIM2 expression following PIM kinase inhibition, resulting in significantly greater inhibition of MM proliferation and survival. Our findings that similar antitumor activity and mechanisms of action are seen in other hematologic malignancies and solid tumors suggest that this 'dual inhibition' of PIM2 may have applicability to a broad range of cancers.
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